专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20100037328A1 CD20-NEGATIVELY CONVERTED B CELL MALIGNANT LYMPHOCYTE CELL LINE AND UTILIZATION OF THE SAME 失效
标题翻译： CD20-阴性转化B细胞恶性淋巴细胞细胞系及其应用
公开(公告)号：US20100037328A1
公开(公告)日：2010-02-11
申请号：US12311281
申请日：2007-09-21
申请人： Tomoki Naoe , Akihiro Tomita , Junji Hiraga
发明人： Tomoki Naoe , Akihiro Tomita , Junji Hiraga
IPC分类号： A01K67/027 , C12N5/0781 , C12Q1/68 , G01N33/574 , A61K49/00 , A61K31/502 , A61P35/00
CPC分类号： G01N33/5052 , A01K67/0271 , A01K2207/12 , A01K2227/105 , A01K2267/0331 , C12N5/0694 , C12N2503/02 , G01N33/5011 , G01N2800/44
摘要： It is intended to provide a tool, a procedure and so on which are useful in developing a therapeutic strategy efficacious in inhibiting or overcoming the resistance against a CD20-directed molecular-targeted drug. Thus, a CD20-negatively converted B-cell malignant lymphocyte cell line is provided. Also, a model animal indicating the pathological conditions of CD20-negatively converted B-cell malignant lymphocyte is provided. Further, a method of screening a substance, which is efficacious against CD20-positive B-cell malignant lymphocyte or CD20-negatively converted B cell malignant lymphocyte, is provided. Furthermore, a drug against CD20-positive B-cell malignant lymphocyte or CD20-negatively converted B-cell malignant lymphocyte, which is characterized by being used together with a CD20-directed molecular-targeted drug, is provided. In one embodiment, a DNA methylase inhibitor or a histone deacetylase inhibitor is employed as the active ingredient.
摘要翻译：旨在提供可用于开发有效抑制或克服对CD20定向分子靶向药物的抗性的治疗策略的工具，程序等。因此，提供CD20阴性转化的B细胞恶性淋巴细胞细胞系。另外，提供了指示CD20-负转换的B细胞恶性淋巴细胞的病理状态的模型动物。此外，提供了筛选对CD20阳性B细胞恶性淋巴细胞或CD20-负向转化的B细胞恶性淋巴细胞有效的物质的方法。此外，提供了抗CD20阳性B细胞恶性淋巴细胞或CD20阴性转化的B细胞恶性淋巴细胞的药物，其特征在于与CD20定向的分子靶向药物一起使用。在一个实施方案中，使用DNA甲基化酶抑制剂或组蛋白脱乙酰酶抑制剂作为活性成分。

2. 发明授权

US08496927B2 CD20 negatively converted B-cell malignant lymphoma cell line and utilization thereof 失效
标题翻译： CD20阴性转化B细胞恶性淋巴瘤细胞系及其利用
公开(公告)号：US08496927B2
公开(公告)日：2013-07-30
申请号：US12311281
申请日：2007-09-21
申请人： Tomoki Naoe , Akihiro Tomita , Junji Hiraga
发明人： Tomoki Naoe , Akihiro Tomita , Junji Hiraga
IPC分类号： A01N63/00 , A01K67/00 , C12Q1/00 , A61K49/00
CPC分类号： G01N33/5052 , A01K67/0271 , A01K2207/12 , A01K2227/105 , A01K2267/0331 , C12N5/0694 , C12N2503/02 , G01N33/5011 , G01N2800/44
摘要： It is intended to provide a tool, a procedure and so on which are useful in developing a therapeutic strategy efficacious in inhibiting or overcoming the resistance against a CD20-directed molecular-targeted drug. Thus, a CD20-negatively converted B-cell malignant lymphocyte cell line is provided. Also, a model animal indicating the pathological conditions of CD20-negatively converted B-cell malignant lymphocyte is provided. Further, a method of screening a substance, which is efficacious against CD20-positive B-cell malignant lymphocyte or CD20-negatively converted B cell malignant lymphocyte, is provided. Furthermore, a drug against CD20-positive B-cell malignant lymphocyte or CD20-negatively converted B-cell malignant lymphocyte, which is characterized by being used together with a CD20-directed molecular-targeted drug, is provided. In one embodiment, a DNA methylase inhibitor or a histone deacetylase inhibitor is employed as the active ingredient.
摘要翻译：旨在提供可用于开发有效抑制或克服对CD20定向分子靶向药物的抗性的治疗策略的工具，程序等。因此，提供CD20阴性转化的B细胞恶性淋巴细胞细胞系。另外，提供了指示CD20-负转换的B细胞恶性淋巴细胞的病理状态的模型动物。此外，提供了筛选对CD20阳性B细胞恶性淋巴细胞或CD20-负向转化的B细胞恶性淋巴细胞有效的物质的方法。此外，提供了抗CD20阳性B细胞恶性淋巴细胞或CD20阴性转化的B细胞恶性淋巴细胞的药物，其特征在于与CD20定向的分子靶向药物一起使用。在一个实施方案中，使用DNA甲基化酶抑制剂或组蛋白脱乙酰酶抑制剂作为活性成分。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式